- recruitingPHASE1, PHASE2
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
This study looks at new drug combinations (Elacestrant and Abemaciclib) for people with breast cancer that has spread to the brain. It aims to find the right dose and see how well the new combination works for ER-positive, HER-2 negative breast cancer.
United States · Belgium · France - not yet recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This study looks at two drugs called dabrafenib and trametinib for various cancers with a specific gene change (BRAF V600). These drugs are already approved for some cancers and researchers want to see if they can help people with other rare cancers or cancers with this same change.
United Kingdom - ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
This study is looking at a new treatment for advanced cancers. We're testing a new drug, BMS-986016, alone and with an existing cancer drug, Nivolumab, to see how safe and effective they are. It's a key first step in understanding these potential new treatments.
Finland · Norway · Denmark - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
This study is testing a cancer drug called capmatinib to see if it can help adults with different types of cancer that share a specific genetic change (MET mutation). It's already approved for some lung cancers, and now researchers want to know if it works for other cancers too.
United Kingdom - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
This study is testing a drug called entrectinib for different cancers in adults and children. It focuses on cancers with a specific change in their cells, called ROS1 gene fusion, to see if entrectinib can be a new treatment option.
United Kingdom - recruitingPHASE3
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
This study is testing a new medicine, PF-08634404, alongside standard chemotherapy for adults with colorectal cancer that has spread. We want to see if this new combination helps more than an existing treatment with chemotherapy for people whose cancer has returned or spread.
United States · Argentina · Australia - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This study is testing a drug called alectinib for different types of cancer that have a special gene change called ALK. It's already used for some lung cancers, and now doctors want to see if it can help other cancers with the same change.
United Kingdom - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
This study is testing a cancer drug called atezolizumab in people with certain cancers that have specific genetic changes. Atezolizumab is already used for some cancers, and this study wants to see if it can help other types of cancer that share these same genetic features.
United Kingdom - recruiting
OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
The OSPREY Registry is looking at how a device called OncoSil™ works in people with locally advanced pancreatic cancer in normal hospital care. It watches how well the device performs and if there are any side effects when used with standard chemotherapy.
Spain · United Kingdom